vs
Side-by-side financial comparison of Caris Life Sciences, Inc. (CAI) and GRAIL, Inc. (GRAL). Click either name above to swap in a different company.
Caris Life Sciences, Inc. is the larger business by last-quarter revenue ($216.8M vs $43.6M, roughly 5.0× GRAIL, Inc.). Caris Life Sciences, Inc. runs the higher net margin — 11.2% vs -227.5%, a 238.7% gap on every dollar of revenue. On growth, Caris Life Sciences, Inc. posted the faster year-over-year revenue change (113.4% vs 14.0%). Caris Life Sciences, Inc. produced more free cash flow last quarter ($55.3M vs $-63.9M).
Caris Life Sciences is a leading precision medicine biotech company specializing in advanced molecular profiling for oncology. It provides actionable genomic and molecular insights to oncologists to personalize cancer treatment plans, and partners with biopharmaceutical firms to accelerate novel cancer drug discovery and development, serving customers across North America, Europe, and key Asia-Pacific markets.
GRAIL, Inc. is an American biotechnology company based in Menlo Park, California founded in 2015 seeking to develop an early cancer screening test for people who do not have symptoms. As a startup it was a subsidiary of Illumina, which bought it outright in 2021.
CAI vs GRAL — Head-to-Head
Income Statement — Q3 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $216.8M | $43.6M |
| Net Profit | $24.3M | $-99.2M |
| Gross Margin | — | — |
| Operating Margin | 15.1% | -285.4% |
| Net Margin | 11.2% | -227.5% |
| Revenue YoY | 113.4% | 14.0% |
| Net Profit YoY | 135.9% | -2.2% |
| EPS (diluted) | $0.08 | $-2.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $43.6M | ||
| Q3 25 | $216.8M | $36.2M | ||
| Q2 25 | $181.4M | $35.5M | ||
| Q1 25 | — | $31.8M | ||
| Q4 24 | — | $38.3M | ||
| Q3 24 | $101.6M | $28.7M | ||
| Q2 24 | $100.0M | $32.0M | ||
| Q1 24 | — | $26.7M |
| Q4 25 | — | $-99.2M | ||
| Q3 25 | $24.3M | $-89.0M | ||
| Q2 25 | $-71.8M | $-114.0M | ||
| Q1 25 | — | $-106.2M | ||
| Q4 24 | — | $-97.1M | ||
| Q3 24 | $-67.7M | $-125.7M | ||
| Q2 24 | $-66.2M | $-1.6B | ||
| Q1 24 | — | $-218.9M |
| Q4 25 | — | -285.4% | ||
| Q3 25 | 15.1% | -346.2% | ||
| Q2 25 | -9.9% | -446.9% | ||
| Q1 25 | — | -482.5% | ||
| Q4 24 | — | -358.0% | ||
| Q3 24 | -59.9% | -640.5% | ||
| Q2 24 | -67.0% | -5133.8% | ||
| Q1 24 | — | -851.1% |
| Q4 25 | — | -227.5% | ||
| Q3 25 | 11.2% | -245.8% | ||
| Q2 25 | -39.6% | -320.7% | ||
| Q1 25 | — | -333.6% | ||
| Q4 24 | — | -253.8% | ||
| Q3 24 | -66.6% | -438.7% | ||
| Q2 24 | -66.2% | -4958.8% | ||
| Q1 24 | — | -819.3% |
| Q4 25 | — | $-2.37 | ||
| Q3 25 | $0.08 | $-2.46 | ||
| Q2 25 | $-7.97 | $-3.18 | ||
| Q1 25 | — | $-3.10 | ||
| Q4 24 | — | $-1.49 | ||
| Q3 24 | $-2.59 | $-3.94 | ||
| Q2 24 | $-2.54 | $-51.06 | ||
| Q1 24 | — | $-7.05 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $755.5M | $249.7M |
| Total DebtLower is stronger | $375.9M | — |
| Stockholders' EquityBook value | $478.4M | $2.6B |
| Total Assets | $984.6M | $2.9B |
| Debt / EquityLower = less leverage | 0.79× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $249.7M | ||
| Q3 25 | $755.5M | $126.9M | ||
| Q2 25 | $721.2M | $127.4M | ||
| Q1 25 | — | $133.9M | ||
| Q4 24 | — | $214.2M | ||
| Q3 24 | — | $853.6M | ||
| Q2 24 | — | $958.8M | ||
| Q1 24 | — | $199.7M |
| Q4 25 | — | — | ||
| Q3 25 | $375.9M | — | ||
| Q2 25 | $373.4M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $2.6B | ||
| Q3 25 | $478.4M | $2.2B | ||
| Q2 25 | $452.9M | $2.3B | ||
| Q1 25 | — | $2.4B | ||
| Q4 24 | — | $2.5B | ||
| Q3 24 | $-2.4B | $2.6B | ||
| Q2 24 | $-2.4B | $2.7B | ||
| Q1 24 | — | — |
| Q4 25 | — | $2.9B | ||
| Q3 25 | $984.6M | $2.6B | ||
| Q2 25 | $955.1M | $2.7B | ||
| Q1 25 | — | $2.8B | ||
| Q4 24 | — | $3.0B | ||
| Q3 24 | — | $3.1B | ||
| Q2 24 | — | $3.3B | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 0.79× | — | ||
| Q2 25 | 0.82× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $62.4M | $-63.8M |
| Free Cash FlowOCF − Capex | $55.3M | $-63.9M |
| FCF MarginFCF / Revenue | 25.5% | -146.5% |
| Capex IntensityCapex / Revenue | 3.3% | 0.2% |
| Cash ConversionOCF / Net Profit | 2.57× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-299.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-63.8M | ||
| Q3 25 | $62.4M | $-63.2M | ||
| Q2 25 | — | $-77.0M | ||
| Q1 25 | — | $-95.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-104.6M | ||
| Q2 24 | — | $-171.8M | ||
| Q1 24 | — | $-207.3M |
| Q4 25 | — | $-63.9M | ||
| Q3 25 | $55.3M | $-63.6M | ||
| Q2 25 | — | $-77.3M | ||
| Q1 25 | — | $-95.1M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-105.6M | ||
| Q2 24 | — | $-173.2M | ||
| Q1 24 | — | $-209.8M |
| Q4 25 | — | -146.5% | ||
| Q3 25 | 25.5% | -175.8% | ||
| Q2 25 | — | -217.6% | ||
| Q1 25 | — | -298.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -368.4% | ||
| Q2 24 | — | -541.7% | ||
| Q1 24 | — | -785.3% |
| Q4 25 | — | 0.2% | ||
| Q3 25 | 3.3% | 1.1% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | 0.2% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 3.4% | ||
| Q2 24 | — | 4.3% | ||
| Q1 24 | — | 9.5% |
| Q4 25 | — | — | ||
| Q3 25 | 2.57× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CAI
| Molecular Profiling Services | $207.6M | 96% |
| Pharma Research And Development Services | $9.2M | 4% |
GRAL
| Screening Revenue | $42.3M | 97% |
| Developmental Services Revenue | $1.3M | 3% |
